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A B S T R A C T
Background
Foot wounds in people with diabetes mellitus (DM) are a common and serious global health issue. Negative pressure wound therapy
can be used to treat these wounds and a clear and current overview of current evidence is required to facilitate decision-making regarding
its use.
Objectives
To assess the effects of negative pressure wound therapy compared with standard care or other adjuvant therapies in the healing of foot
wounds in people with DM.
Search methods
In July 2013, we searched the following databases to identify reports of relevant randomised controlled trials (RCTs): CochraneWounds
Group Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL); The Database of Abstracts of Reviews
of Effects (DARE); The NHS Economic Evaluation Database; Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed
Citations); Ovid EMBASE; and EBSCO CINAHL.
Selection criteria
Published or unpublished RCTs that evaluate the effects of any brand of negative pressure wound therapy in the treatment of foot
wounds in people with diabetes, irrespective of publication date or language of publication. Particular effort was made to identify
unpublished studies.
Data collection and analysis
Two review authors independently performed study selection, risk of bias assessment and data extraction.
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Main results
We included five studies in this review randomising 605 participants. Two studies (total of 502 participants) compared negative pressure
wound therapy with standard moist wound dressings. The first of these was conducted in people with DM and post-amputation
wounds and reported that significantly more people healed in the negative pressure wound therapy group compared with the moist
dressing group: (risk ratio 1.44; 95% CI 1.03 to 2.01). The second study, conducted in people with debrided foot ulcers, also reported
a statistically significant increase in the proportion of ulcers healed in the negative pressure wound therapy group compared with the
moist dressing group: (risk ratio 1.49; 95% CI 1.11 to 2.01). However, these studies were noted to be at risk of performance bias, so
caution is required in their interpretation. Findings from the remaining three studies provided limited data, as they were small, with
limited reporting, as well as being at unclear risk of bias.
Authors’ conclusions
There is some evidence to suggest that negative pressure wound therapy is more effective in healing post-operative foot wounds and
ulcers of the foot in people with DM compared with moist wound dressings. However, these findings are uncertain due to the possible
risk of bias in the original studies. The limitations in current RCT evidence suggests that further trials are required to reduce uncertainty
around decision making regarding the use of NPWT to treat foot wounds in people with DM.
P L A I N L A N G U A G E S U M M A R Y
Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Diabetes mellitus is a common condition that leads to high blood glucose concentrations, with around 2.8 million people affected
in the UK (approximately 4.3% of the population). Some people with diabetes can develop ulcers on their feet. These wounds can
take a long time to heal, be painful and become infected. Ulceration of the foot in people with diabetes can also lead to a higher
risk of amputation of parts of the foot or leg. Generally, people with diabetes are at a higher risk of lower-limb amputation than
people without diabetes. Negative pressure wound therapy is a wound treatment which involves applying suction to a wound; it is
used increasingly around the world but it is not clear how effective it is. It also expensive compared with treatments such as dressings.
We found five randomised controlled trials that compared negative pressure wound therapy with other treatments. We found some
preliminary evidence that negative pressure wound therapy increases the healing of foot wounds on people with diabetes compared
with other treatments. However, the findings are not conclusive and more, better quality randomised controlled trials are required.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
NPWT compared to Moist dressings for healing post-operative wounds in people with diabetes
Patient or population: patients with healing post-operative wounds in people with diabetes
Settings:
Intervention: NPWT
Comparison: Moist dressings
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Moist dressings NPWT
Proportion of wounds
healed
Follow-up: mean 16
weeks
Study population RR 1.44
(1.03 to 2.01)
162
(1 study)
⊕⊕©©
low1,2
388 per 1000 559 per 1000
(400 to 780)
Moderate
Time to ulcer healing
Follow-up: mean 16
weeks
Study population HR 1.91
(1.21 to 2.99)
162
(1 study)
⊕⊕©©
low1,3
388 per 1000 609 per 1000
(448 to 770)
Moderate
Amputation
Follow-up: mean 16
weeks
Study population RR 0.25
(0.05 to 1.10)
162
(1 study)
⊕©©©
very low1,4
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106 per 1000 26 per 1000
(5 to 116)
Moderate
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 There was the potential for performance bias as unblinded health professionals were able to make decisions about undertaking closure
surgery that could then have resulted more wounds being closed (and classed as healed) or amputated in one group compared with
the other.
2 The confidence interval around the estimate of relative risk is consistent with a 3% relative increase in healing with NPWT to a 101%
relative increase in healing with NPWT.
3 The confidence interval around the estimate hazard ratio is consistent with a 21% relative increase in the hazard of healing with NPWT
to a 199% relative increase in the hazard of healing with NPWT.
4 The confidence interval around the estimate of relative risk is consistent with a 95% relative reduction in chance of healing with NPWT
to a 10% relative increase in healing with NPWT.
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B A C K G R O U N D
Description of the condition
Diabetes mellitus (DM) is a chronic condition caused by impaired
regulation of blood glucose levels. Normally the hormone insulin
regulates blood glucose, but in people with type 1DMproduction
of insulin no longer occurs. Type 2 DM is characterised by cellular
insensitivity to insulin, allied with a failure of compensatory pan-
creatic insulin secretion. In the UK approximately 90% of people
with DM have Type 2 (Department of Health 2010).
In the adult population of the UK, the prevalence of diagnosed
DM is approximately 4.5% - or 2.9 million people (Diabetes UK
2011). In the United States (USA) the 2010 prevalence of diag-
nosed DM (all ages) was approximately 6% (Centers for Disease
Control and Prevention 2011), and in Canada in 2008/09, for
those over one year of age, it was 6.8% (Public Health Agency
of Canada 2011). Many cases of DM, however, are undiagnosed,
and, when these cases are also taken into consideration, the ad-
justed 2010 prevalence estimates increase to 10.3% for the USA,
9.2% for Canada, 7.8% for India, and 10.8% for Mexico. The
global prevalence of DM is projected to rise further over the next
20 years, largely driven by aging populations, obesity and increas-
ingly sedentary lifestyles (Shaw 2010).
DM is a serious health problem because of the associated glucose-
related complications of the disease, including the specific ’mi-
crovascular’ complications such as retinopathy, nephropathy and
neuropathy, i.e. damage to the retina, kidney and nerves. Cou-
pled with this, insulin resistance increases the risk of macrovas-
cular complications including cardiovascular, cerebrovascular and
peripheral arterial disease (PAD). The particular combination of
peripheral neuropathy and peripheral vascular disease contributes
to the development of foot ulceration, which may lead to surgical
debridement or amputation of the foot or lower limb.
Foot wounds in people with diabetes mellitus
There are two main types of foot wounds that can affect people
with DM, which are summarised below.
Foot ulcers
Both PAD and neuropathy are risk factors for the development of
chronic foot ulceration in people withDM(Pecoraro 1990; Reiber
1999). PAD and neuropathy can occur separately (the ischaemic
foot or the neuropathic foot respectively), or in combination (the
neuroischaemic foot). Foot ulceration is reported to affect 15% or
more of people with DM at some time in their lives (Reiber 1996;
Singh 2005). Estimates of the prevalence of foot ulceration vary,
but around 1% to 4% of people with DM have foot ulcers at any
given time (Abbott 2002; Kumar 1994). Figures for 2008 showed
that, for those people with DM in receipt of US Medicare, the
prevalence of the presence of least one foot ulcer was 8% (Margolis
2011).
An ulcer forms as a result of damage to the epidermis (outermost
layer of skin) and subsequent loss of underlying tissue. A foot ul-
cer is specifically defined by the International Consensus on the
Diabetic Foot as a wound that extends through the full thickness
of the skin below the level of the ankle (Apelqvist 2000a). This
definition is not concerned with duration of the ulcer (although
some definitions of chronic ulceration require a duration of six
weeks or more), and includes ulcers that extend to muscle, tendon
and bone. The severity of foot ulcers in people with DM can be
graded using a number of systems. The Wagner wound classifi-
cation system was one of the first described and has, historically,
beenwidely used, although it is now rarely used in clinical practice.
This system assessed ulcer depth and the presence of osteomyelitis
(bone infection) or gangrene and graded them as: grade 0 (pre- or
post-ulcerative lesion), grade 1 (partial/full-thickness ulcer), grade
2 (probing to tendon or capsule), grade 3 (deep with osteitis (in-
flammationof the bone)), grade 4 (partial foot gangrene) and grade
5 (whole foot gangrene) (Wagner 1981). Newer grading systems,
such as the PEDIS system (Schaper 2004), the University of Texas
Wound Classification System (Oyibo 2001), and SINBAD have
been developed since (Ince 2008), with the SINBAD system being
the best validated (Karthikesalingam 2010).
Foot ulcers in people with DM have a serious impact on health-
related quality of life, particularly with respect to physical func-
tioning and role-limitations due to physical and emotional issues
(Nabuurs-Franssen 2005; Ribu 2006). They also represent amajor
use of health resources, incurring costs not only for dressings, but
also staff costs (for podiatrists, nurses, doctors), tests and investiga-
tions, antibiotics and specialist footwear. In 2010-11 the estimated
NHS spend on foot ulceration and amputation in people with
DM in England was GBP 639 to GBP 662 million (Kerr 2012).
The economic impact is also high in terms of the personal costs
to patients and carers, for example, costs associated with lost work
time and productivity while the patient is unable to bear weight
or is hospitalised. As many as 85% of foot-related amputations are
preceded by ulceration (Apelqvist 2000b; Pecoraro 1990).
In terms of ulcer healing, a meta-analysis of trials in which peo-
ple with neuropathic ulcers received good wound care, reported
that 24% of ulcers completely healed by 12 weeks and 31% by 20
weeks (Margolis 1999). Reasons for delayed healing can include:
infection (especially osteomyelitis (bone infection)), co-morbidi-
ties such as peripheral vascular disease and end-stage renal disease,
and the size and depth of an ulcer at presentation. Even when
ulcers do heal, the risk of recurrence is high. Pound 2005 reported
that 62% of ulcer patients (from a sample of 231 people) became
ulcer-free at some stage over a 31-month observation period, how-
ever, 40% of the ulcer-free group went on to develop a new, or re-
current, ulcer after a median of 126 days. Indeed, the ulcer recur-
rence rate over five years can be as high as 70% (Dorresteijn 2010;
Van Gils 1999). Failure of ulcers to heal may result in amputation,
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and people with DM have a 10 to 20-fold higher risk of losing a
lower limb, or part of a lower limb, to non-traumatic amputation
than those without DM (Morris 1998; Wrobel 2001).
Surgical wounds to the foot in people with diabetes mellitus
The risk of lower limb amputation is much greater for people with
DM than for those without. The major underlying pathophysi-
ology associated with amputation are neuropathy and ischaemia.
Lower limb amputation can have devastating consequences for
people’s health status and health-related quality of life (Tennvall
2000), as well as having a large financial impact on healthcare
providers and users. In the UK, from 1 April 2007 to 31 March
2010, a total of 16,693 lower limb amputations were recorded in
people with DM (Holman 2012). Of these 10,216 were classed as
minor amputations (usually defined as below the ankle joint), and
6,477 as major amputations (usually defined as above the ankle
joint). The UK cost of ’foot procedures related to diabetes or arte-
rial disease and procedures to amputation stumps’ was estimated as
approximately GBP 17million over 2009/10. In the US, the 2008
prevalence of lower extremity amputation in Medicare recipients
was 1.8%, with a total mean annual Medicare reimbursement cost
for each person with DM and a lower extremity amputation esti-
mated at USD 54,000. Ulcers are often considered to be chronic
wounds, whilst post-surgical amputation sites are considered to be
acute wounds, unless they do not heal (Ubbink 2008a).
As well as amputation debridement (regarded as an important
component of the treatment of ’chronic’ foot wounds, such as
ulcers or non-healing surgical wounds, in people with DM) can
sometimes be undertaken as a surgical procedure. Debridement
involves removal of dead tissue and callus (along with pressure-re-
lief/offloading, treatment of infection and revascularisation, where
necessary). As in other areas of wound care, sharp (surgical) de-
bridement of diabetic foot wounds is recommended in guide-
lines in order to promote wound healing by ’converting’ a chronic
wound to an acute wound via removal of dead tissue and slough
(Steed 2006). Whilst this practice is common, there is little ev-
idence that surgical debridement promotes healing of diabetic
foot wounds (Eneroth 2008; Lebrun 2010), but debridement of
necrotic tissue with eschar from wounds, including diabetic foot
wounds, can sometimes be a requirement prior to the use of wound
treatments such as negative pressure wound therapy (NPWT)
(KCI 2012b)
Description of the intervention
Any intervention that promotes healing, or reduces amputation
rates, or both, in foot wounds in people with DM would be make
an important difference, and a number of health technologies are
marketed with these outcomes in mind. The evidence, however,
for the clinical and cost-effectiveness of these technologies is fre-
quently lacking. A recent suite of Cochrane reviews (Dumville
2011a; Dumville 2011b; Dumville 2012a; Dumville 2012b), and
an associated mixed treatment comparison (Dumville 2012c),
found no robust evidence to suggest that any one dressing was
more effective than another in terms of healing foot ulcers in peo-
ple with DM. A similar conclusion was drawn following a system-
atic review by the International Working Group of the Diabetic
Foot (Game 2012).
Negative pressure wound therapy (NPWT) is a technology that
is currently used widely in wound care. NPWT is promoted for
use on complex wounds - including foot wounds in people with
DM - as an adjunct (additional) therapy to standard care. NPWT
involves the application of a wound dressing through which a
negative pressure (or vacuum) is applied, with wound and tissue
fluid being collected into a canister. The intervention was devel-
oped in the 1990s, and the uptake of NPWT in the healthcare
systems of developed countries has been dramatic. A US Depart-
ment of Health report estimated that between 2001 and 2007
Medicare payments for NPWT pumps and associated equipment
increased from USD 24 million to USD 164 million (an increase
of almost 600%) (Department of Health and Human Services
2009). Initially only one NPWT manufacturer supplied NPWT
machines (the V.A.C system: KCI, San Antonio Texas), however,
as the NPWT market has grown, a number of different commer-
cial NPWT systems have been developed, with machines becom-
ing smaller and more portable. Indeed, the most recent introduc-
tion to the market is a single use, or ’disposable’, negative pressure
product. Ad hoc, homemade, negative pressure devices are also
used, especially in resource-poor settings. These devices tend to
use simple wound dressings, such as gauze, or transparent occlu-
sive (non-permeable) dressings, with negative pressure generated
in hospital by vacuum suction pumps.
A number of different healthcare professionals prescribe and apply
NPWT, and it is now used both in secondary and primary (com-
munity) care, particularly following the introduction of ambula-
tory systems.Whilst theNPWT systems outlined above differ in a
number of respects - such as type of pressure (constant or cyclical)
applied to the wound, the material in contact with the surface of
the wound and also the type of dressing used - the principle of
applying a negative pressure to the wound in a closed environment
is the same for all products.
How the intervention might work
NPWTostensibly assists inwoundmanagement by collectinghigh
volumes of wound exudate, reducing the frequency of dressing
changes by keeping anatomically-challenging wounds (such foot
wounds) clean, and reducing odour. Manufacturers, however, also
suggest that the application of mechanical force to the wound
provides biologically-plausible processes by which wound healing
is promoted, i.e. the drawing together of wound edges, increased
perfusion, and the removal of infectiousmaterial and exudate (KCI
2012a). NPWTmight have a beneficial effect by encouraging off-
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loading (i.e. reducing theweight takenon the foot, as someNPWT
systems make ambulation difficult) and preventing unnecessary
dressing changes and repeated exposures to the environment.
There are some potentially negative aspects associated with
NPWT; these include wound maceration (softening due to expo-
sure to liquid), retention of dressings, and wound infection as well
as other injuries (FDA 2011). NPWT devices are usually worn
continually by patients during treatment, they can interfere with
mobility, and, anecdotally, are often noisy, which prevents some
patients from sleeping.
Why it is important to do this review
NPWT is an expensive - yet widely used - health technology for
the management of complex wounds, and there is potential for its
use to increase. Indeed, in the UK NPWT can now be prescribed
by primary care physicians (who may not have specific training in
wound care). A Cochrane review that examines the clinical effec-
tiveness ofNPWT for chronic wounds has already been published,
but, given that foot wounds in patients with DM present unique
challenges though their varied and complex pathophysiology, we
feel this focused review will add value to previous publications. In-
deed, this proposed review will include all foot wounds in people
with DM (both surgical and non-surgical), and an important fo-
cus will be clarification and consideration of the study populations
and the impact of their aetiologies (causes) on interpretation of
trial evidence in this area.This scope means that, for people with
DM,wewill present evidence from foot wounds caused by surgical
debridement and recent amputation, in addition to evidence for
the effects of NPWT on non-surgically treated foot ulcers or other
non-healing foot wounds. This approach will provide an up-to-
date and comprehensive overview of evidence for NPWT for all
types of foot wound in people with DM, with a focus on consid-
ering the type of diabetic foot wound to which current evidence
relates.
Furthermore, as a previous study has highlighted (Peinemann
2008), there is a large number of trials of NPWT that have ei-
ther been discontinued or remain unpublished. Peinemann et al
found that nine out of 19 completed or discontinued NPWT ran-
domised controlled trials (RCTs) were unpublished. Furthermore,
these nine unpublished studies included themajority of planned or
analysed patients (70% of the total participants). Thus any review
of NPWT requires a clear strategy for investigating unpublished
sources of literature and the reasons for discontinuation with, or
without, non-publication of studies.
In conclusion, we feel that a Cochrane review that comprehen-
sively identifies, interrogates, presents and synthesises evidence of
the effects of NPWT on the outcomes of foot wounds in people
with DM will be a valuable piece of research. The review is rele-
vant to clinical policy and consumer decision-makers in provid-
ing a robust overview of current evidence, and to researchers and
funders in highlighting areas of uncertainty that may be addressed
by future research. This is relevant, since the draft National In-
stitute of Health and Clinical Excellence (NICE) Clinical Guide-
line “Diabetic foot problems: In-patient management of diabetic
foot problems” (NICE 2011), recommends that “negative pressure
wound therapy should not be routinely used to treat diabetic foot
problems, but may be considered in the context of a clinical trial
or as rescue therapy (when the only other option is amputation).”
O B J E C T I V E S
To assess the effects of negative pressure wound therapy compared
with standard care or other therapies in the healing of foot wounds
in people with diabetes mellitus (DM).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published or unpublished RCTs that evaluate the effects of any
brand of NPWT in the treatment of diabetic foot wounds, irre-
spective of publication status or language of publication.
Types of participants
Trials recruiting people with Type 1 or Type 2 DM, with foot
wounds below the ankle, regardless of underlying aetiology (i.e.
ischaemic, neuropathic or neuroischaemic). This includes diabetic
foot ulcers, or wounds resulting from amputation or other surgical
treatment, or both. We included trials involving people of any age
and from any setting.
Where trials with broad inclusion criteria have recruited partici-
pants with diabetic foot wounds as part of a larger chronic wound
study population e.g. alongside participants with pressure ulcers
or leg ulcers, these trials were excluded unless the results for the
subgroup of participants with diabetic foot wounds were reported
separately or were available from authors on request.
Types of interventions
Any brand of NPWT (including studies that investigated home-
made or ad hoc negative pressure devices) compared with stan-
dard care (such as advanced wound dressings and gauze) or other
treatments, so that NPWT was the only difference between trial
arms.
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Types of outcome measures
Primary outcomes
Complete wound healing
Trialistsmeasure and reportwoundhealing inmany differentways,
including: time to complete wound healing, proportion of wounds
healed during follow-up and rates of change of wound size. For
this review we regarded trials that reported one or more of the
following, as providing the best measures of outcome in terms of
relevance and rigour.
• Time to wound healing within a specific time period,
correctly analysed using survival, time-to-event, approaches -
ideally with adjustment for relevant co-variates such as size of
wound at baseline (start of trial). We assumed that the period of
time in which healing could occur was the duration of the trial,
unless otherwise stated.
• Number of wounds completely healed during follow-up
(frequency of complete healing).
• Change (and rate of change) in wound size, when adjusted
for baseline size - ideally analysed using multi-level modelling or
(multiple) linear regression.
We note that, since wound healing is a subjective outcome, it can
be at high risk of measurement bias when outcome assessment is
not blinded.
Amputation
• Major amputation (defined as any amputation above the
ankle joint).
• Minor amputation (defined as any amputation below the
level of the ankle joint).
Secondary outcomes
• Participant health-related quality of life/health status
(measured using a standardised generic questionnaire such as
EQ-5D, SF-36, SF-12 or SF-6 or wound-specific questionnaires
such as the Cardiff wound impact schedule at noted time
points.We did not include ad hoc measures of quality of life that
were not likely to be validated and would not be common to
multiple trials.
• Other adverse events, including infection and pain
(measured using survey/questionnaire/data capture process or
visual analogue scale), where a clear methodology for the
collection of adverse event data was provided.
• Resource use (including measurements of resource use such
as number of dressing changes, nurse visits, length of hospital
stay and re-operation/intervention).
• Wound recurrence.
Search methods for identification of studies
Electronic searches
In July 2013, we searched the following databases to identify re-
ports of RCTs:
• Cochrane Wounds Group Specialised Register (searched 30
July 2013);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (2013, Issue 7);
• The Database of Abstracts of Reviews of Effects (DARE)
(2013, Issue 7);
• The NHS Economic Evaluation Database (2013, Issue 7);
• Ovid MEDLINE (1946 to January Week 30 2013);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations July 29, 2013);
• Ovid EMBASE (1974 to 2013 Week );
• EBSCO CINAHL (1982 to 26 July 2013).
The following search strategy was used in the Cochrane Central
Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor: [Foot Ulcer] explode all trees437
#2 MeSH descriptor: [Diabetic Foot] explode all trees390
#3 (diabet* near/3 ulcer*):ti,ab,kw 524
#4 (diabet* near/5 (foot or feet)):ti,ab,kw 847
#5 (diabet* near/5 wound*):ti,ab,kw 171
#6 (diabet* near/3 defect*):ti,ab,kw 14
#7 MeSH descriptor: [Amputation] explode all trees299
#8 MeSH descriptor: [Amputation Stumps] explode all trees44
#9 (diabetic near/3 amputat*):ti,ab,kw 31
#10 MeSH descriptor: [Debridement] explode all trees411
#11 (debrid* or slough* or deslough*):ti,ab,kw 1141
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or
#11 2336
#13 MeSH descriptor: [Negative-Pressure Wound Therapy] ex-
plode all trees62
#14 MeSH descriptor: [Suction] explode all trees719
#15 MeSH descriptor: [Vacuum] explode all trees115
#16 MeSH descriptor: [Drainage] explode all trees1896
#17 (“negative pressure” or negative-pressure or TNP):ti,ab,kw
502
#18 (sub-atmospheric or subatmospheric):ti,ab,kw 20
#19 ((seal* next surface*) or (seal* next aspirat*)):ti,ab,kw 17
#20 (wound near/2 suction*):ti,ab,kw 62
#21 ((foam next suction) or (suction next dressing*)):ti,ab,kw 0
#22 (vacuum assisted closure or VAC):ti,ab,kw 234
#23 ((vacuum next therapy) or (vacuum next dressing*) or (vac-
uum next seal*) or (vacuum next assist*) or (vacuum near closure)
or (vacuumnext compression) or (vacuumnext pack*) or (vacuum
next drainage)):ti,ab,kw 162
#24 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #
21 or #22 or #23 87386
#25 #12 and #24 403
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We adapted this strategy to search Ovid MEDLINE, Ovid EM-
BASE and EBSCO CINAHL. We combined the Ovid MED-
LINE search with the Cochrane Highly Sensitive Search Strategy
for identifying randomised trials in MEDLINE: sensitivity- and
precision-maximising version (2008 revision) (Lefebvre 2011).We
combined the EMBASE search with the Ovid EMBASE filter de-
veloped by the UK Cochrane Centre (Lefebvre 2011). We com-
bined the CINAHL searches with the trial filters developed by the
Scottish IntercollegiateGuidelinesNetwork (SIGN2012).We did
not restrict studies with respect to language, date of publication
or study setting.
We searched the following clinical trials registries:
• ClinicalTrials,gov (http://www.clinicaltrials.gov/) Febuary
2013;
• WHO International Clinical Trials Registry Platform (
http://apps.who.int/trialsearch/Default.aspx) Febuary 2013;
• Current Controlled Trials (http://www.controlled-
trials.com/); Febuary 2013.
Searching other resources
Wewere keen to explore sources of unpublished data. Tomaximise
identification of unpublished or studies that were not located dur-
ing the search stage we searched the reference lists of the included
studies and of previous systematic reviews. We also examined the
content of European Wound Management conference proceed-
ings (2012-2013) and systematic reviews in the field that might
refer to data we had not found, and contacted key manufacturers
(KCI, and Smith & Nephew) to ask about unpublished (as well
as on-going) work. We also contacted key authors in the field.
Data collection and analysis
Selection of studies
Two review authors independently assessed the titles and abstracts
of retrieved studies for relevance. After this initial assessment, we
obtained full copies of all studies felt to be potentially relevant.
Two review authors independently checked the full papers for
eligibility; disagreements were resolved by discussion and, where
required, the input of a third review author.We recorded all reasons
for exclusion of studies for which we had obtained full copies.
We completed a PRISMA flowchart to summarise this process
(Liberati 2009).
Data extraction and management
We extracted and summarised details of the eligible studies using
a data extraction sheet. Two review authors extracted data inde-
pendently and resolved disagreements by discussion, drawing on
a third reviewer where required. Where data were missing from
reports, we attempted to contact the study authors to obtain this
information. We included studies published in duplicate once, but
extracted the maximal amount of data. We extracted the following
data, where possible:
• country of origin;
• participants’ type of DM;
• wound aetiology (e.g. PAD)
• type of wound, including site on foot;
• unit of investigation (per patient) - single wound, or foot,
or patient, or multiple wounds on the same patient;
• care setting;
• number of participants randomised to each trial arm;
• eligibility criteria and key baseline participant data;
• details of the dressing/treatment regimen received by each
group;
• details of any co-interventions;
• number of post-amputation/debridement wounds closed
surgically;
• primary and secondary outcome(s) (with definitions);
• outcome data for primary and secondary outcomes (by
group);
• duration of follow-up;
• number of withdrawals (by group);
• adverse events;
• publication status of study; and,
• source of funding for trial.
Assessment of risk of bias in included studies
Two review authors independently assessed each included study
using the Cochrane Collaboration tool for assessing risk of bias
(Higgins 2011). This tool addresses six specific domains, namely,
sequence generation, allocation concealment, blinding, incom-
plete outcome data, selective outcome reporting and other issues
(e.g. extreme baseline imbalance, issues with unit of investigation).
We assessed blinding of participants and health professionals, and
blinded outcome assessment separately.We were aware that blind-
ing of participants and health professionals to treatment received
would not be possible, but it was important to understand if, and
how, studies had compensated for this where required, i.e. where
outcomes such as wound closure and amputation could be at risk
of performance bias. We completed a ’Risk of Bias’ table for each
eligible study. Disagreements about risk of bias assessment were
resolved by discussion. Where possible, when a lack of reported in-
formation resulted in an unclear decision, authors were contacted
for clarification.
We classified trials as being at high risk of bias if they were rated
’high’ for one or more of three key criteria, namely, randomisa-
tion sequence, allocation concealment and blinded outcome as-
sessment. We also considered the potential for performance and
measurement bias for each primary and secondary outcome ex-
tracted.
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Measures of treatment effect
Where possible, studies were grouped according to wound type.
Where possible, we presented the outcome results for each trial
with 95% confidence intervals (CI). We reported estimates for di-
chotomous outcomes (e.g. ulcers healed during a particular time
period) as risk ratios (RR). We used the RR rather than odds ratio
(OR), since, when event rates are high, as is the case for many
trials reporting wound healing, ORs (when interpreted as RR)
can give an inflated impression of the effect size (Deeks 2002).
We planned to report outcomes relating to continuous data (e.g.
percentage change in ulcer area) as mean differences (MD) and
overall effect size (with 95% CI). Where a study reported data on
time-to-healing (the probability of healing over a consecutive time
period) we planned to report and plot these data (where possible)
using hazard ratio estimates. However, where the hazard ratio was
not reported, but data regarding the number of events and the P
value for a log rank test (reported to at least two significant figures)
were reported, we employedmethods proposed by Parmar 1998 to
calculate the hazard ratio indirectly. Where log rank test P values
were published to only one significant figure the robustness of the
calculated hazard ratio for the highest possible P value was investi-
gated to test robustness of estimates. Hazard ratios and associated
95% CIs were then calculated using the inverse variance option in
RevMan (RevMan 2011).
Unit of analysis issues
We recorded whether trials presented outcomes in relation to a
wound, a foot, a participant or as multiple wounds on the same
participant. We also recorded occasions where multiple wounds
on a participant were (incorrectly) treated as independent within a
study, rather than having within-patient analysis methods applied.
This was recorded as part of the risk of bias assessment. For wound
healing and amputation, unless otherwise stated, where the num-
ber of wounds appeared to equal the number of participants, we
treated the wound as the unit of analysis. For other adverse event
outcomes, in order to facilitate further analyses, we aimed to es-
tablish whether data were presented at the level of the participant,
because in this area there is potential for data to refer to multiple
events occurring to a single person (or wound per person), which
means that data cannot be analysed further without violating the
assumption of independence.
Dealing with missing data
It is common to have data missing from trial reports. Exclud-
ing participants post-randomisation from the analysis, or ignor-
ing those participants who are lost to follow-up compromises the
randomisation, and potentially introduces bias into the trial. In
individual studies, where data on the proportion of ulcers healed
were presented, we assumed that if randomised participants were
not included in an analysis, their wound did not heal (i.e. they
would be considered in the denominator but not the numerator).
Where a trial did not specify participant group numbers prior to
drop-out, we presented only complete case data. In a time-to-heal-
ing analysis using survival analysis methods, drop-outs should be
accounted for as censored data. Hence all participants contributed
to the analysis. Such analysis assumes that drop-outs are missing
at random (i.e. not associated with time-to-healing). We present
data for area change, and for all secondary outcomes, as a complete
case analysis.
Assessment of heterogeneity
We considered both clinical and statistical heterogeneity. Wher-
ever appropriate, that is, where studies appeared similar in terms
of wound type, intervention type, duration and outcome type,
we planned to pooled data using meta-analysis (conducted using
RevMan 5.1 (RevMan 2011)).We planned to assess statistical het-
erogeneity using the Chi² test (a significance level of P less than
0.1 was considered to indicate heterogeneity) and the I² estimate
(Higgins 2003). The I² estimate examines the percentage of total
variation across studies due to heterogeneity rather than to chance.
Values of I² higher than 50% indicate a high level of heterogene-
ity. In the absence of clinical heterogeneity and in the presence of
statistical heterogeneity (I² over 50%), we envisioned using a ran-
dom-effects model, however, we did not anticipate pooling studies
where heterogeneity was very high (I² over 75%). Where there
was no clinical or statistical heterogeneity we used a fixed-effect
model.
Data synthesis
We combined studies using a narrative overview, with meta-anal-
yses of outcome data where appropriate (in RevMan 5). The de-
cision to include studies in a meta-analysis depended on the avail-
ability of treatment effect data and assessment of heterogeneity.
For time-to-event data, we planned to use the inverse variance
method on the estimated hazard ratio and standard error, when
reported or calculated from available data.
Where relevant, and possible, we planned to conduct sensitivity
analyses to investigate the potential impact of studies at high risk
of bias on pooled results.
Subgroup analysis and investigation of heterogeneity
We considered whether there was potential heterogeneity between
wounds types, i.e. foot ulcers and surgical wounds resulting from
surgical debridement of an ulcer, or amputation on any part of a
diabetic foot. Where there was evidence of between-trial hetero-
geneity in trial-level co-interventions, especially off-loading, we
envisaged a sub-group analysis being conducted based on varia-
tions in co-interventions, e.g. all trial participants reported to re-
ceive adequate offloading protocol/advice being compared with
trial participants who received unclear advice about offloading -
however, this was not required. Finally, depending on the number
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and heterogeneity of included studies, we considered using meta-
regression to investigate wound aetiology as a possible explanatory
variable.
Summary of findings
We present themain results of the review in ’Summary of findings’
tables, which provide key information concerning the quality of
evidence, the magnitude of effect of the interventions examined,
and the sum of available data on the main outcomes, as recom-
mended by the Cochrane Collaboration (Schunemann 2011a).
We included the following main outcomes in the ’Summary of
findings’ tables:
• complete wound healing;
• amputation.
The ’Summary of findings’ tables include an overall grading of the
evidence related to each of the main outcomes, using the GRADE
approach (Schunemann 2011b).
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies for full details of the studies identified. Two stud-
ies are awaiting classification, one requiring further details before a
decision regarding eligibly can be decided (Tuncel 2013) and one
requiring translation (Sun 2007). Two studies have been identi-
fied as on-going: ISRCTN34166832 and ISRCTN90301130. To
date ISRCTN34166832 has not recruited any participants rele-
vant to this review (personal communication, see Characteristics
of ongoing studies).
Included studies
A total of five studies randomising 605 participants were included
in this review. Four studies were two-armed (Armstrong 2005;
Blume 2008; Karatepe 2011; Mody 2008), and one was three-
armed (Novinš ak 2010). All studies were parallel studies. Two
studies were undertaken in the USA (Armstrong 2005; Blume
2008), one in Turkey (Karatepe 2011); one in Croatia (Novinš ak
2010) and one in India (Mody 2008). Populations evaluated in
the studies were people with DM and foot wounds: resulting from
amputation (Armstrong 2005) and classed as foot ulcers (Blume
2008; Karatepe 2011; Mody 2008; Novinš ak 2010). NPWT
treatments for all studies except Novinš ak 2010 (no details pro-
vided) and Mody 2008 (non-commercial system) were the VAC®
system (Kinetic Concepts Inc., TX, USA). Comparison arms re-
ceived a variety of treatments including:
(a) Advanced moist wound therapy (moist wound therapy with
alginates, hydrocolloid, foam or hydrogel dressings (Armstrong
2005); advanced moist wound therapy dressings, predominantly
hydrogels and alginates (Blume 2008); moist dressings (not gauze)
(Novinš ak 2010); or,
(b) Gauze (moist gauze dressing (Mody 2008), dry gauze (
Novinš ak 2010), and sterilized gauze (Karatepe 2011)).
Follow-up times were: eight weeks (Novinš ak 2010); 16 weeks
(Armstrong 2005; Blume 2008), or unclear (Karatepe 2011;
Mody 2008). In terms of primary outcomes, four studies reported
proportion of wounds healed (Armstrong 2005; Blume 2008;
Novinš ak 2010; Mody 2008); three reported time-to-healing
data (Armstrong 2005; Blume 2008; Karatepe 2011), and two re-
ported data on major and/or amputations recorded during study
follow-up (Armstrong 2005; Blume 2008). For further details see
Table 1 .
Excluded studies
Thirteen studies were excluded after investigation of the full text.
In total: one study did not have a populationwith foot wounds and
the study population could not be confirmed in a further study;
four studies had study populations with multiple wound types and
we were unable to obtain separate data on people with DM and
foot wounds; four studies contained no relevant outcomes; two
studies were not considered to be RCTs, and one study evaluated
NPWT as part of a range of treatments, so this intervention was
not the only difference between trial groups. See Characteristics
of excluded studies for further details.
See Figure 1 for study flow diagram.
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Figure 1. Study flow diagram (Liberati 2009)
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Risk of bias in included studies
See Figure 2; Figure 3 for corresponding figures.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Adequacy of randomisation process
All included studies were described as ’randomised’ with four stud-
ies providing information to confirm that adequate sequence gen-
eration had taken place (Armstrong 2005; Blume 2008; Karatepe
2011; Mody 2008); these were judged to be at low risk of bias
for this domain (all studies using computer-generated sequences).
Novinš ak 2010 did not described how randomisation took place,
and were judged to be at unclear risk of bias for this domain.
Allocation concealment
Two of the five studies were judged to be at low risk of bias
for allocation concealment (Armstrong 2005; Blume 2008). Both
studies employed “sealed envelopes containing opaque, black pa-
per labelled with assigned treatment and patient ID number that
were sequentially numbered and provided to each site”, which
we deemed to be robust. The remaining studies did not contain
enough detail for us to make a judgement for this domain, and so
were judged as being at unclear risk of bias.
Blinding
All studies were deemed to be at unclear risk of bias. We note
that whilst Armstrong 2005 and Blume 2008 appeared to under-
take some blinded outcome assessment, we questioned the poten-
tial impact of non-blinded decisions regarding the use of further
surgery. There was no indication that the decision to undertake
closure or amputation was guided by the protocol to ensure that
there were no differences in performance between groups for rea-
sons other than the treatment received (e.g. surgery was an option
only when wounds reached a particular size or condition), or was
undertaken by a blinded committee to ensure consistency between
groups. Given the non-blinded status of health professionals to
treatment received, there may have been the potential for perfor-
mance bias in promoting surgery (thus closure or amputation) in
one group compared with the other.
Incomplete outcome data
Two studies were deemed to be at low risk of bias for attrition
bias (Armstrong 2005; Mody 2008). Three studies were classed
as being at unclear risk of bias: Blume 2008 reported a small
number of post-randomised exclusions, as well as being unclear
about whether there was a large number of early censoring in the
analysis; Karatepe 2011 and Novinš ak 2010 reported very little
information regarding participant flow through the study.
Effects of interventions
See: Summary of findings for the main comparison NPWT
compared to Moist dressings for healing post-operative wounds in
people with diabetes; Summary of findings 2 NPWT compared
toMoist dressings for debrided foot ulcers in people with diabetes;
Summary of findings 3NPWT compared to Gauze dressings for
debrided foot ulcers in people with diabetes
Outcome data are summarised in Table 1.
1. NPWT compared with moist (non-gauze) dressings
a. Post-operative wounds
One study was included in this analysis. Armstrong 2005 ran-
domised 162 participants who had previously undergone diabetic
foot amputation (to the trans-metatarsal level) to receive NPWT
(dressing changed every 48 hours) or treatment with alginate, hy-
drocolloid, foam or hydrogel dressings. Participants were followed
for 16 weeks.
Primary outcomes
Proportion of wounds healed
There was a statistically significant increase in the number of
wounds healed in the group treated with NWPT (43/77; 56.0%)
compared with the moist dressing group (33/85; 38.8%) (RR
1.44; 95% CI 1.03 to 2.01) (Analysis 1.1). This meant that peo-
ple in the NPWT group had 1.44 times the ’risk’ of healing of
people in the moist dressing group. The study was classed as be-
ing at low risk of bias in all assessed domains except blinding,
for which it was classed as unclear. Whilst ’wounds healed’ did
undergo blinded outcome assessment, health professionals were
aware of treatment received during the study and could decide to
close wounds via surgery. There was no indication in the study
report(s) that this decision to stop NPWT treatment and recom-
mend surgery was guided by specific decision rules (e.g. size of
wound), or was made in a blinded fashion. Thus, potentially, dif-
ferent numbers and types of participants within groups may have
had wounds ’closed’ - introducing bias if this decision was based
only on knowledge of treatment being received. In total, 12/77
(22%) of participants in the NPWT group had wounds classed as
healed following closure via surgery compared with 8/85 (9%) of
participants in the dressing group. From study data it is not clear if
NPWT improves wounds so that surgery becomes an appropriate
option for more people, or whether there is a bias here. If wounds
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healed after surgical closure are treated as a secondary outcome,
and only wounds that healed by secondary intention (i.e. without
surgery) are considered, the finding becomes non-significant (RR
1.37: 95% CIs 0.89 to 2.10) (analysis not presented graphically
here).
Time to ulcer healing
Armstrong 2005 reported that time to complete wound closure
was significantly shorter in the NPWT group (median time-to-
healing of 56 days) compared with the moist dressing group (me-
dian time-to-healing 77 days). We note that these reported figures
do not agree with the Kaplan-Meier curve reported in the paper,
where median values seemed to be higher. The results of the time
to wound closure analysis were reported by the authors as being a
statistically significant result (P value 0.005: results from a log rank
test). Using the observed numbers of events and total numbers in
each group together with the reported P value to calculate the log-
hazard ratio and its standard error (Parmar 1998), we calculated
the log hazard ratio to be 0.645 (0.69 where maximum P value of
log rank test assumed, as only reported to one significant figure)
with a standard error of 0.23, which equals a hazard ratio of 1.91
with 95% CI 1.21 to 2.99. Thus our calculations suggest that, at
any point during follow-up, the hazard (or chance) of healing in
those allocated to NWPT was 1.9 times that of those allocated
to the moist dressing group (Analysis 1.2). As above, there is the
potential for the time-to-healing outcome to be biased by the un-
dertaking of closure surgery in a non-blinded and non-protocol-
driven manner.
Amputations
A greater proportion of people in the moist dressing group had an
amputation though this difference was not statistically significant
(NWPT group 2/77 (3%); moist dressing group 9/85 (11%) (RR
0.25, 95%CI 0.05 to 1.10) (Analysis 1.3). Five of the amputations
in the moist dressing group were classed as major, but there were
no major amputations in the NPWT-treated group. We note that
the study was not powered to detect a difference in number of
amputations, and the number of events was low. Also it is not
clearwhether decisions about amputationwere covered by decision
rules in the protocol to avoid any potential performance bias.
Secondary outcomes
Adverse events
There was no statistically significant difference in the number
of participants experiencing one or more adverse events in the
NPWT group (40/77; 52%) compared with the moist dressing
group (46/85; 54%) (RR 0.96; 95% CI 0.72 to 1.28) (Analysis
1.4). Neither was there a statistically significant difference when
only treatment-related adverse events were considered (RR 0.90;
95% CI 0.40 to 2.06) (Analysis 1.4).
Resource use
Armstrong 2005 study reported an average total cost per partici-
pant of USD 26,972 in the NPWT group compared with USD
36,887 in the most dressing group - no standard deviation data
were reported, and data have not been analysed further here. The
difference was driven by those in the dressing group reporting a
greater number of: outpatient visits, dressing changes and surgi-
cal debridements. No cost effectiveness or cost utility analysis to
reflect incremental differences in cost to benefit (with uncertainty
around these) was reported.
b. Foot ulcers
Two studies were included in this analysis. Blume 2008 ran-
domised 341 participants withDM and foot ulcers toNPWT (ap-
plied according to manufacturer’s instructions) or advanced moist
wound-therapy dressings (predominately hydrogels and alginates)
with a 16-week follow-up. Study inclusion criteria specified that
ulcers should be Wagner Grades 2 or 3 and with an area of 2 cm
2 or greater. Novinš ak 2010 randomised 19 participants with
complicated diabetic foot ulcers to NPWT (no further details pro-
vided) or moist dressings (no further details provided) with a two-
month follow-up.
Primary outcomes
Proportion of wounds healed
Blume 2008 there was a statistically significant increase in the
number of wounds healed in the NWPT group (73/172; 42%)
compared with themoist dressing group (48/169; 28%) (RR 1.49;
95% CI 1.11 to 2.01) (Analysis 1.1). This means, on average,
the NPWT group were49% more likely to heal compared with
the moist dressing group. The study was classed as being at low
risk of bias for all domains except for incomplete outcome data
and blinded outcome assessment, which were classed as unclear.
Incomplete outcome assessment was classed as unclear because
31% of participants in the NPWT group and 25% in the dressing
group were classed as ’discontinued’ in the study CONSORT flow
diagram. Reasons for discontinuation included adverse events, in-
effective treatment withdrawal by the investigator, and death. It
is not clear whether participants who were discontinued for rea-
sons other than death were also censored from the analysis, rather
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than being followed up. If discontinuation did result in censor-
ing in this open trial it may have introduced bias. Blinded out-
come assessment was classed as unclear for similar reasons to the
Armstrong 2005 trial. Unblinded health professionals were able
to make decisions about doing closure surgery that did not appear
to be pre-specified by the study protocol; this could have resulted
more wounds being closed (and classed as healed) in one group.
Novinš ak 2010 reported that 90% of participants treated in the
NPWT group (n = 7) had a healed wound compared with 75% in
the moist dressing group (n = 12). Data were not analysed further
since actual numbers of participants healed were not provided,
and we were unable to calculate how the figure of 90% had been
reached in a group of seven participants (since 6/7 equals 86%).
The study report contained limited data and was classed as being
at unclear risk of bias for all domains.
Time to ulcer healing
Blume 2008 reported that time to complete wound closure was
significantly shorter in the NPWT group, with median time-to-
healing of 96 days (95% CI 75 to 112), compared with the moist
dressing group, inwhich themediannumber of participants healed
was not reached over the 16-week follow-up. A log rank test re-
turned a P value of 0.001. Using the method of Parmar 1998 the
log hazard ratio was calculated as 0.598 (0.581 where maximum
P value of log rank test assumed as only reported to one significant
figure) with a standard error of 0.182, which equals a hazard ratio
of: 1.82 with 95% CI 1.27 to 2.60. These calculations suggested
that, at any point during follow-up, the hazard (or chance) of
healing for those allocated to NWPT was 1.8 times that of those
allocated to the moist dressing group (Analysis 1.2). As above,
there was potential for the time-to-healing outcome to have been
affected by the undertaking of closure surgery in a non-blinded
and non-protocol-driven way.
Amputations
Blume 2008 reported a statistically significant reduction in the
number of amputations between the NWPT group (7/172; 4%)
compared with themoist dressing group (17/169; 10%) (RR 0.40,
95% CI 0.17 to 0.95) (Analysis 1.3). Five of the amputations in
theNPWTgroupwere classed asmajor, comparedwith four in the
moist dressing group. Again, it was not clear whether, in order to
avoid any potential performance bias, decisions about amputation
were covered by decision rules in the protocol .
Secondary outcomes
Resource use
Blume 2008 reported the mean estimated total costs of inpatient
services per participant as USD 5206 (95% CI USD 3172 to
7561) in the NPWT group compared with USD 8570 (95% CI
USD 5922 to USD 11,432) in the dressing group. No further
resource use/cost data were presented, and data were not analysed
in the context of costs versus benefits.
c. Pooled data
We did not pool any data for this comparison due to clinical
heterogeneity between studies.
Summary of NPWT compared with moist (non-gauze)
wound dressings
There is some evidence of greater healing of diabetic foot wounds
(resulting from partial amputation or ulceration) over a 16-week
periodwithNPWTcomparedwithmoist dressings.Data also sug-
gest that people allocated toNPWTwere at a significantly reduced
risk of amputation compared with those allocated to moist dress-
ings. There is some weak evidence that NPWT might also be a
cheaper treatment thanmoist dressings.However, the studies from
which these findings are drawn are at unclear risk of bias. It is im-
portant to recognise that, potentially, decisions regarding closure
surgery and amputation might have been affected by health pro-
fessionals’ knowledge of treatments received (Summary of findings
for the main comparison; Summary of findings 2).
2. NPWT compared with gauze dressings
a. Post operative wounds
No included studies
b. Foot ulcers
Three studies were included in this analysis of foot ulcers. Karatepe
2011 randomised 67 participants with DM and foot ulcers to
NPWT or daily wound care that consisted of debridement and
treatment of gangrenous tissue, where required, and use of ster-
ilized gauze dressing. Participants were followed for an unspeci-
fied period. Mody 2008 recruited a total of 48 participants: 15 of
these were reported to have diabetic foot ulcers, with nine treated
with wet to dry gauze, and six treated with a locally-constructed
NPWT machine. Novinš ak 2010 was described in the previous
comparison.
17Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Primary outcomes
Proportion of wounds healed
Karatepe 2011 did not report data on proportion of wounds
healed. Mody 2008 reported that 1/6 (16.6%) participants allo-
cated to NPWT had healed (by secondary intention) compared
with 4/9 (44.4%) allocated to dressings (one by secondary in-
tention and three by delayed primary closure, i.e. stitching after
surgery) RR: 0.38 95% CI 0.05 to 2.59 (Analysis 2.1). Novinš ak
2010 reported that 90% of participants treated in the NPWT
group (n = 7) had a healed wound compared with 50% in the
moist dressing group (n = 8). Data were not analysed further, as
study figures were not provided, and we were unable to calculate
how 90% had been reached in a group of seven participants (as 6/
7 equals 86%). The study report contained limited data, and was
classed as being at unclear risk of bias for all domains.
Time to ulcer healing
Karatepe 2011 reported that median time-to-healing was 3.9
weeks in the NPWT group compared with 4.4 weeks in the gauze
group. Limited data were presented and a hazard ratio could not
be calculated. Novinš ak 2010 did not report data on time to
ulcer healing.
Amputation
The three studies did not report relevant data about amputation
(Karatepe 2011; Mody 2008; Novinš ak 2010).
Secondary outcomes
Health related quality of life
Karatepe 2011 reported collection of SF-36 data - however these
were not presented, and were not available.
c. Pooled data
Due to limited data we did not pool any data for this comparison.
Summary of NPWT compared with gauze dressings
There was limited RCT-derived data from which to draw con-
clusions regarding the comparative effectiveness of NPWT when
compared to gauze dressings Summary of findings 3.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
NPWT compared to Moist dressings for debrided foot ulcers in people with diabetes
Patient or population: patients with debrided foot ulcers in people with diabetes
Settings:
Intervention: NPWT
Comparison: Moist dressings
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Moist dressings NPWT
Proportion of wounds
healed
Follow-up: mean 16
weeks
Low risk of healing1 RR 1.49
(1.11 to 2.01)
341
(1 study)
⊕⊕©©
low2,3
340 per 1000 507 per 1000
(377 to 683)
Moderate risk of healing1
530 per 1000 790 per 1000
(588 to 1000)
High risk of healing1
650 per 1000 968 per 1000
(722 to 1000)
Time to healing
Follow-up: mean 16
weeks
Low risk of healing4 HR 1.82
(1.27 to 2.60)
341
(1 study)
⊕⊕©©
low2,5
340 per 1000 531 per 1000
(410 to 661)
Moderate risk of healing4
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530 per 1000 747 per 1000
(617 to 860)
High risk of healing4
650 per 1000 852 per 1000
(736 to 935)
Amputation
Follow-up: mean 16
weeks
Study population RR 0.40
(0.17 to 0.95)
341
(1 study)
⊕⊕©©
low2,6
101 per 1000 40 per 1000
(17 to 96)
Moderate
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Baseline risk of healing obtained from external source in which data from 27,630 patients with a diabetic neuropathic foot ulcer was
used to develop a simple prognostic model to predict likelihood of ulcer healing (Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA.
Diabetic neuropathic foot ulcers: predicting which ones will not heal. Am J Med. 2003;115:627-31). It is important to note that given
an outcome of ulcer healing, low risk refers to a low risk of healing and thus reflects the most severe patient populations. Conversely
high risk refers to a high risk of healing.
2 There was the potential for performance bias as unblinded health professionals were able to make decisions about undertaking closure
surgery that could then have resulted more wounds being closed (and classed as healed) or amputated in one group compared with the
other.
3 The confidence interval around the estimate of relative risk is consistent with a 11% relative increase in healing with NPWT to a 101%
relative increase in risk of healing with NPWT.
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4 Baseline risk of healing obtained from external source in which data from 27,630 patients with a diabetic neuropathic foot ulcer was
used to develop a simple prognostic model to predict likelihood of ulcer healing (Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA.
Diabetic neuropathic foot ulcers: predicting which ones will not heal. Am J Med. 2003;115:627-31). It is important to note that given an
outcome of ulcer healing, low risk refers to a low risk of healing and thus reflects the most severe patient populations. Conversely high
risk refers to a high risk of healing.
5 The confidence interval around the estimate hazard ratio is consistent with a 27% relative increase in the hazard of healing with NPWT
to a 160% relative increase in the hazard of healing with NPWT.
6 The confidence interval around the estimate of relative risk is consistent with a 83% relative reduction in amputation risk with NPWT to
a 5% relative reduction in amputation risk with NPWT.
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NPWT compared to Gauze dressings for debrided foot ulcers in people with diabetes
Patient or population: patients with debrided foot ulcers in people with diabetes
Settings:
Intervention: NPWT
Comparison: Gauze dressings
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Gauze dressings NPWT
Proportion of wounds
healed
Follow-up: mean 30 days
Low risk of healing1 RR 0.38
(0.05 to 2.59)
15
(1 study)
⊕©©©
very low2,3
340 per 1000 129 per 1000
(17 to 881)
Moderate risk of healing1
530 per 1000 201 per 1000
(27 to 1000)
High risk of healing1
650 per 1000 247 per 1000
(33 to 1000)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Baseline risk of healing obtained from external source in which data from 27,630 patients with a diabetic neuropathic foot ulcer was
used to develop a simple prognostic model to predict likelihood of ulcer healing (Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA.
Diabetic neuropathic foot ulcers: predicting which ones will not heal. Am J Med. 2003;115:627-31). It is important to note that given
an outcome of ulcer healing, low risk refers to a low risk of healing and thus reflects the most severe patient populations. Conversely
high risk refers to a high risk of healing.
2 Several domain had unclear risk of bias recorded.
3 The confidence interval around the estimate of relative risk is consistent with a 95% relative reduction in risk of healing with NPWT to a
159% relative increased risk of healing with NPWT.
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D I S C U S S I O N
Summary of main results
There is some evidence that NPWT is a clinically effective treat-
ment (in terms of reducing time-to-healing and reducing risk of
amputations) for foot wounds in people with DM. This relates to
wounds that are post-operative and of relatively short duration as
well as chronic, but debrided, ulcers. These findings are predomi-
nantly based on two studies that compared the VAC® system with
moist wound dressings (Armstrong 2005; Blume 2008). However,
it is important to note that the risk of bias in these two studies
was difficult to assess and the results presentedmust be considered
in this light. Evidence from the three other included studies was
limited by small sample sizes, the collection and reporting of lim-
ited outcome data, as well as a lack of detail about the type of foot
wounds being assessed. Individually and collectively, these three
studies make a limited contribution to the findings presented here.
Quality of the evidence
The two largest studies included in this review Armstrong 2005
and Blume 2008 were similar in design (both were funded by the
manufacturer of VAC® - KCI) although they evaluated differ-
ent types of foot wounds. Whilst these studies were deemed to
be at low risk of bias for random sequence generation and alloca-
tion concealment, the risk of performance and detection bias for
both was unclear, since study reports suggested that key decisions
regarding the treatment of wounds, such as closure surgery and
further amputation, were made by unblinded health profession-
als and were not guided by a trial protocol in a way that would
minimise potential performance bias. This issue has been noted
in other reviews (e.g. Medical Advisory Secretariat 2006), and the
validity of combining wounds closed by secondary intention and
those closed by surgery questioned. For Blume 2008 it was also
unclear whether the studies analysis was as close to an intention-
to-treat analysis as would be possible with the data collected.
We also note that the included studies had limited information
about the receipt of important adjunctive therapies such as off-
loading. Whilst these therapies were often noted as being delivered
where required, it would be useful to know whether their delivery
was balanced between studies groups, as they are such an important
part of routine care.
Potential biases in the review process
In this, as in other areas, all RCT study data should be available
in the public domain to enable decision-making to be informed
by the most comprehensive evidence base possible. However, pre-
vious work highlighted the large number of RCTs of NPWT that
have either been terminated, or have been completed but remain
unpublished (Peinemann 2008). Extensive searching here did not
locate further unpublished studies beyond those previously identi-
fied (Peinemann 2008), However, there may well be other studies
of which we are not aware. We also note that some studies were
excluded because they evaluated interventions on multiple wound
types, and specific data for foot wounds in people with DM were
not available.
Agreements and disagreements with other
studies or reviews
One previous systemic review with a title suggesting a focus on
diabetic foot ulcers has been published (Noble-Bell 2008). The
review included four studies that were classed as RCTs, however
two of these were excluded from our review ((Etoz 2007 (n =
24); McCallon 2000 (n = 10)), as they used a method of alloca-
tion based on alternation and we consider this a quasi-randomised
method of allocation. One further study was excluded from our
review as it did not report relevant outcome data (Eginton 2003).
The remaining study included in our review (Armstrong 2005).
TheNoble-Bell 2008 reviewhighlighted the positive findings from
Armstrong 2005, whilst recommending further larger RCTs in a
wider number of diabetic foot-wound groups. We summarise the
same RCT findings but recommend more cautious interpretation
of Armstrong 2005.
All other relevant key reviews have assessed the effectiveness of
NPWTacross wound types, including foot wounds in people with
DM.The relevantCochrane review concludes that “Trials compar-
ingTNP [NPWT]with alternative treatments for chronic wounds
have methodological flaws and data do demonstrate a beneficial
effect of TNP on wound healing, however more, better quality re-
search is needed” (Ubbink 2008b). However, no studies included
in theUbbink 2008b review are included here; - partly because this
previous review only considered chronic wounds, partly because
we did not consider unadjusted change in wound size data as an
outcome and finally, because more recent studies are available e.g.
Blume 2008.
Finally, recent NICE guidelines reviewed the data regarding use of
NPWT for treatment of foot wounds in people with DM (NICE
2011). They included three studies: two of which we include here
(Armstrong 2005; Blume 2008) and one which we excluded (as
above) Etoz 2007. The review conducted within the Guideline
also found that “two RCTs with a total number of 497 partici-
pants showed that participants who received NPWT with stan-
dard wound care were significantly less likely to have an amputa-
tion, and significantlymore likely to have completewound closure,
when compared with participants who received standard wound
care alone.” However, the GRADE assessment of the evidence in
the NICE guideline regarded this as low quality evidence. The
NICE Guideline Development Group recommended that, “ . . . a
health economic evaluation should be carried out to further assess
its [NPWT] cost effectiveness as an adjunctive treatment for dia-
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betic foot problems . . . ” (page 128). The Guideline Development
Group also “recommended the use of the intervention in the con-
text of a clinical trial or as a rescue therapy to prevent amputation”
(page 128). The findings from our review agree that further robust
RCT research would help to reduce uncertainty regarding the ef-
fectiveness of NPWT in the treatment of foot wounds in people
with DM. Robust studies should focus on ensuring confidence
that differences in outcomes, such as healing and amputations,
can be attributed to the intervention, rather than occurring as a
result of bias. We note that, despite these recommendations, we
found only one on-going RCT in the UK (ISRCTN34166832),
and this is not specific to foot wounds in people with DM .
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review draws together all relevant studies that have evalu-
ated negative pressure wound therapy (NPWT) for the treatment
of foot wounds in people with DM. The robust review process
considered only randomised controlled trials (RCTs), excluding
studies that indicated that participants had been allocated using
alternation.
Data from the two largest included studies suggested that NPWT
may be an effective treatment in terms of healing debrided foot
ulcers and post-operative amputation wounds in people withDM.
However, these studies could be at risk of bias. Thus, any potential
change in practice regarding the use of NPWT would need to be
informed by clinical experience and acknowledge the uncertainty
around this decision due to the quality of data.
Implications for research
There is scope for future research in this area - probably large
robust RCTs. Any future studies should, alongside standard areas
of good practice, consider the following points:
• have appropriate follow-up times in order to capture
maximal information about important outcomes such as time-
to-healing and amputations (e.g. 12 months);
• collect and report detailed adverse event data (e.g., infection
and pain);
• collect and report health-related quality of life data using
validated measures;
• ensure protocols are designed to minimise the potential for
performance bias.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Armstrong 2005
Methods 2-arm RCT; undertaken in USA (in wound and academic centres)
Participants 162 adult participants
Inclusion criteria: presence of: (1) wound from a diabetic foot amputation to the trans-
metatarsal level of the foot; (2) adequate perfusion; (3) University of Texas grade 2 or 3
Exclusion criteria: people presenting with (1) active Charcot arthropathy of the foot;
(2) wounds resulting from burns; (3) venous insufficiency; (4) untreated cellulitis or
osteomyelitis (after amputation); (5) collagen vascular disease; (6) malignant disease in
the wound; or people treated with: (7) corticosteroids; (8) immunosuppressive drugs or
chemotherapy; (9) NPWT (in the last 30 days); (10) growth factors; (11) normothermic
therapy; (12) hyperbaric medicine; (13) bioengineered tissue products (in the last 30
days)
Key baselines co-variates:
Wound area (cm2):
Group A: 19.2 (SD = 17.6)
Group B: 22.3 (SD = 23.4)
Wound duration (months):
Group A: 1.8 (SD = 5.9)
Group B: 1.2 (SD = 3.9)
75.3% of the study population had wounds that were < 30 days’ duration (classed as
acute wounds by the author) and 24.7% had wounds that were > 30 days’ duration
(classed as chronic wounds by authors)
Interventions Group A (n = 85): moist wound therapy with alginates, hydrocolloid, foam or hydrogel
dressings - adhering to standardised guidelines at the discretion of attending clinician.
Dressings changed every other day unless recommended by treating clinician
Group B (n = 77): NPWT (VAC® system) no information provided regarding the
pressure applied or the cycle (e.g. constant/cyclical etc); dressing changes every 48 h.
Treatment conducted until wound closure or completion of 112 day assessment
All participants received: (1) off-loading therapy, preventatively and therapeutically as
indicated - a pressure relief sandal or walker was provided for all participants; (2) sharp
debridement within 2 days of randomisation and as deemed necessary by treating clini-
cian; and, (3) measurement of pre-albumin, albumin and HbA1c levels in 7 days before
entering the study. Low pre-study albumin levels resulted in consultation with nutri-
tionist, and dietary supplement initiated if needed.
Outcomes Primary outcome: (1) number of wounds completely healed (defined as 100% re-epithe-
lialisation without drainage and INCLUDED closure via surgery where the decision for
surgical closure was made by treating clinician); (2) time to wound healing; (3) ampu-
tation
Secondary outcomes: (1) other adverse events (serious and non-serious); (2) resource use
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Armstrong 2005 (Continued)
Notes Follow-up: 112 days (16 weeks)
Outcome assessment: based on data from wound assessments and digital photographs
taken by treatment clinicians at days 0, 7, 14, 28, 42, 56, 84 and 112
A secondary analysis of trial data reported that 75% of wounds were ≤ 1 month in
duration (classed by authors as acute) and 25% were > 1 month in duration (classed by
authors as chronic). We note that mean baseline values for ulcer duration were obviously
very skewed
Funding: study funded by KCI - manufacturers of the VAC® intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was accomplished
by using www.randomizer.org to generate
15 blocks of 10 random numbers each.”
Comment: adequate methodology
Allocation concealment (selection bias) Low risk Quote: “Numbers were systematically as-
signed to each treatment group, and sealed
envelopes containing opaque, black paper
labelled with assigned treatment and pa-
tient ID number were sequentially num-
bered and provided to each site. The black
paper was added to ensure that the contents
of the envelopes were not visible prior to
opening.”
Comment: adequate methodology
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: it is understandably not pos-
sible to blind participants and patients to
whether or not they receive NPWT. How-
ever, given this, it is important that any
decision-making that might be affected by
performance bias is recognised and blind-
ing is introduced where possible. We
note that unblinded health professionals
were able to make decisions about closure
surgery that could then have resulted in
more wounds being closed (and classed as
healed) or amputated in one group com-
pared to the other. As a result of this we
classed the risk of bias for this domain as
unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Neither patients nor investiga-
tors were masked to the randomised treat-
ment assignment . . . However, notes that
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Armstrong 2005 (Continued)
the masking component of the study dealt
specifically with planimetry measurements
from digital photographs . . . concordance
between the investigator and the digital
planimetry provided independent confir-
mation of the primary efficacy endpoint of
complete wound healing.”
Comment: assessment of healing seems to
have had a blinded component
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no evidence of incomplete out-
come data
Other bias Low risk No evidence of other bias
Blume 2008
Methods 2-arm RCT; undertaken in USA
Participants 342 adult participants
Inclusion criteria: (1) stage 2 or 3 (Wagner’s scale) calcaneal, dorsal or planter foot ulcer;
ulcer≥ 2 cm2 in area after debridement; (3) adequate blood perfusion (various tests and
cut-offs reported)
Exclusion criteria: (1) recognised active Charcot disease; (2) ulcers resulting from elec-
trical, chemical or radiation burns; (3) collagen vascular disease; (4) ulcer malignancy;
(5) untreated osteomyelitis or cellulitis; (6) uncontrolled hyperglycaemia; (7) inadequate
lower extremity perfusion; (8) pregnant or nursing mothers; or ulcer treatment within
30 days of trial start with (9) normothermic or hyperbaric oxygen therapy, (10) cor-
ticosteroids, (11) immunosuppressive drugs, (12) chemotherapy, (13) recombinant or
autologous growth factor products, (14) skin and dermal substitutes; or (15) use of any
enzymic debridement treatment
Key baselines co-variates:
Wound area (cm2):
Group A: 11.0 (SD = 12.7)
Group B: 13.5 (SD = 18.2)
Wound duration (months)
Group A: 6.9 (SD = 12.2)
Group B: 6.6 (SD = 10.8)
Interventions Group A (n = 169): advanced moist wound therapy dressings used according to guide-
lines/local protocols - noted as being predominantly hydrogels and alginates
Group B (n = 172): NPWT (VAC® system) applied according to manufacturer’s in-
structions, but no information provided about the pressure applied or the cycle (e.g.
constant/cyclical etc). Treatment continued until wound closure, or until there was suf-
ficient granulation tissue formation for healing by primary and secondary intention
All participants received: (1) assessment and debridement of ulcers within 2 days of
randomisation; (2) off-loading therapy as deemed necessary
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Blume 2008 (Continued)
Outcomes Primary outcome: (1) number of wounds completely healed (defined as 100% re-ep-
ithelialisation without drainage or dressing requirement and INCLUDED closure via
surgery where the decision for surgical closure was made by treating clinician); (2) time
to wound healing; (3) amputation
Secondary outcomes: (1) other adverse events (serious and non-serious); (2) resource use
Notes Follow-up: 112 days (16 weeks)
Outcome assessment: participants examined weekly for the first 4 weeks and then every
other day until day 112, or ulcer closure by any means. Participants achieving closure
were followed up at 3 and 9 months
Funding: study funded by KCI - manufacturers of the VAC® intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote:“Randomization was accomplished by gen-
erating blocks of numbers through http://www.ran-
domizer.org.”
Comment: adequate methodology
Allocation concealment (selection bias) Low risk Quote: “Numbers were assigned to a treatment
group and sealed in opaque envelopes containing
black paper labelled with treatment and patient ID.
Envelopes were sequentially numbered before clini-
cal trial site distribution. At patient randomisation,
treatment was assigned on the basis of the next se-
quentially labelled envelope.”
Comment: adequate methodology
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: It is understandably not possible to blind
participants and patients to whether or not they re-
ceive NPWT. However, given this, it is important
that any decision-making that might be affected by
performance bias is recognised and blinding is in-
troduced where possible. We note that unblinded
health professionals were able to make decisions
about undertaking closure surgery that could then
have resultedmore wounds being closed (and classed
as healed) or amputated in one group compared with
the other. As a result of this we classed the risk of
bias for this domain as unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Blinded photographic evaluation was con-
ducted.”
Comment. whilst the main report has no discussion
of blinded outcome assessment, it is mentioned in
the conference abstract describing the study. How-
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Blume 2008 (Continued)
ever as with Armstrong 2005 we note that unblinded
health professionals in 1 group were able to make de-
cisions about undertaking closure surgery that could
then have resulted more wounds being closed (and
classed as healed) or amputated. As a result of this
we classed the risk of bias for this domain as unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 3 participants were excluded from analy-
sis in each arm as they did not receive the trial treat-
ment allocated. There were relatively low numbers
of exclusions, although ideally data on these partici-
pants would have been included in the RCT report.
Additionally, 31% of participants in the NPWT
group and 25% in the dressing group were classed
as being ’discontinued’ for reasons that included ad-
verse events, ineffective treatment and also death. It
is not clear whether participants whowere discontin-
ued for reasons other than death were also censored
from the analysis, rather than being followed up. If
discontinuation did result in censoring in this open
trial it may have introduced bias
Other bias Low risk No evidence of other bias
Karatepe 2011
Methods 2-arm RCT; undertaken in Turkey
Participants 67 adult participants.
Inclusion criteria: diabetic foot ulcers
Exclusion criteria: not reported
Key baselines co-variates:
Wound area (cm2):
Group A: 29.7 (SD 5.2)
Group B: 35.7 (SD 6.4)
Wound duration (weeks):
Group A: 8.8 (SD 7.2)
Group B: 11.3 (9.2)
Interventions Group A (n = 37): conventional wound care treatment (described as daily wound care,
debridement and treatment of gangrenous tissue where required and use of sterilized
gauze dressing)
Group B (n = 30): NPWT (VAC® system)
Clinical measures included standard diabetic treatment, daily wound care including
antiseptic bath, debridement, toe removal for gangrene when necessary, and wound care
with conventional methods or VAC®.
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Karatepe 2011 (Continued)
Outcomes Primary outcome: time-to-healing
Secondary outcomes: health-related quality of life measured with SF-36 (not clearly
reported)
Notes Follow-up: final SF-36 form completed 1 month after wound healing (mean in 4th
month of study)
Outcome assessment: healing time calculated as the time from hospital admission to re-
epithelization
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation of the patients was ar-
ranged by the free use web based system (http://
www.tufts.edu\~gdall/PLAN.HTM)”
Comment: classed as an adequate method
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Other bias Low risk No evidence of other risk of bias
Mody 2008
Methods 2-arm RCT; undertaken in India
Participants 48 participants (recruited from inpatient wards), 15 of whom were reported to have DM
and a foot ulcer. Data for these 15 participants only are presented
Inclusion criteria: people admitted to general surgery, physical medicine, and rehabil-
itation wards and referred by the surgical consultants for care of an acute or chronic
extremity, sacral, or abdominal wound that could not be treated with primary closure
Exlusion criteria: (1) ischaemic wounds; or wounds: (2) in anatomical locations where
an adequate seal around the wound site could not be obtained; (3) with exposed bowel or
blood vessels; (4)with necrotic tissue that could not be debrided; (5)with communicating
fistulae; (6) with malignancy; (7) with recent grafts; or (8) presence of osteomyelitis; or
(9) patient receiving therapeutic anticoagulation
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Mody 2008 (Continued)
Key baselines co-variates (foot ulcers in people with diabetes only):
Wound area (cm2):
Group A: 48.1 (SD = 53.5)
Group B: 25.7 (SD = 9.7)
Wound duration (days):
Group A: 5.2 (SD = 2.3)
Group B: 8.5 (SD = 8.3)
Interventions Group A (n = 9): saline-soaked gauze and dry pads used to cover the wound. Dressing
changes typically performed twice daily; frequency adjusted according to the judgment
of the treating physician
Group B (n = 6): locally-constructed (homemade) device: a sterilized, porous packing
material obtained from a local source was cut to fit the wound. A 14-French suction
catheter was tunnelled into the packing material, which then was placed into the wound
cavity. A sterile adhesive plastic drape (Dermincise, Vygon, UK) was cut to overlap the
surrounding skin and applied over the packing material, forming an airtight seal. Tubing
was used to attach the free end of the suction catheter to a wall suction canister. The
TNP timer was placed in circuit between the wall suction apparatus and the wall suction
canister
The TNP timer, constructed from local electronics, was designed to cycle wall suction
intermittently using a simple timed switch and a system of valves. For the study protocol,
the timer was set to cycle for 2 minutes on, followed by 5 minutes off. Wall suction
pressure was set at 125 mmHg. In sensitive wounds, suction was reduced to a tolerable
level (usually 50 mmHg to 100 mmHg) until it could be comfortably increased. For
oedematous wounds, the suction was kept on a continuous setting until oedema had
been reduced and an intermittent regimen could be followed. The dressing was changed
every 2 days unless otherwise scheduled by the treating physician.Wounds were debrided
as required to keep the wound bed free of necrotic tissue. Patients receiving NPWT who
no longer required hospitalisations for their primary diagnosis, or could not afford to
remain in the hospital, remained in the study with conventional wound dressings in the
outpatient setting, but outcomes were analysed in the original treatment groups
Wounds in both treatment groups were debrided before dressing application
Outcomes Primary outcome: number of days to satisfactory healing, defined as complete wound
closure by secondary intention or wound readiness for delayed primary closure as deter-
mined by the study investigator and treating surgeon
Secondary outcomes: none reported separately for foot ulcers
Notes Participants were followed until wound closure or being lost to follow-up for an average
of 26.3 days (+/- 18.5) in the control and 33.1 days (+/- 37.3) in the treatment group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Wounds that met inclusion and exclusion
criteria were assessed for size (in a manner that al-
lowed blinding) and then block-randomized using a
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Mody 2008 (Continued)
concealed computer-generated table in a 1-to-2 ratio
of TNP closure versus conventional wound dress-
ing.”
Comment: adequate method
Allocation concealment (selection bias) Unclear risk Quote: “Following enrolment, wound size was as-
sessed using computer-aided measurements of digi-
tal photographs and block-randomized to the study
arms using a concealed allocation table.”
Comment: unclear how allocation concealment was
conducted
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Seems that participants were analysed in groups as
randomised
Other bias Unclear risk No evidence of other risk of bias
Novinš ak 2010
Methods 3-arm RCT; undertaken in Croatia
Participants 27 adult participants
Inclusion criteria: complicated diabetic ulcer (sic) managed to international guidelines
for treatment protocol (confirmed with the author that these were all foot wounds)
Exclusion criteria: revascularization, reconstruction and amputation procedures were not
considered in this study
Key baselines co-variates: not reported
Wound duration (months): not reported
Interventions Group A (n = 8): classic gauze
Group B (n = 12): moist dressings
Group C (n = 7): NPWT
Surgical debridement, off-loading, co-morbidity treatment and appropriate wound care
were performed
Outcomes Primary outcome: healing rate (author defined as wound closure - personal contact)
Notes Follow-up: 2 months, extracted from abstract only
Risk of bias
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Novinš ak 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Other bias Unclear risk No evidence of other risk of bias
Abbreviations
< = less than
> = more than
≤ = less than or equal to
≥ = more than or equal to
h = hour(s)
NPWT = negative pressure wound therapy
RCT = randomised controlled trial
SD = standard deviation
TNP = topical negative pressure (synonym for NPWT)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Armstrong 2012 Included multiple wounds types. Unable to obtain diabetic foot wound data separately
Braakenburg 2005 Included multiple wounds types. Unable to obtain diabetic foot wound data separately
Chong No relevant outcome reported
Eginton 2003 No relevant outcome reported
Etoz 2007 Not an RCT, as participants allocated using alternation
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(Continued)
Foo 2004 No relevant outcome reported
Maggio 2010 Treatment with NPWT was not the only systematic difference between groups (intervention group
receiving NPWT also received autologous fibroblasts and skin grafting)
McCallon 2000 Not an RCT, as participants allocated using alternation. Coin flipped for first participant and then
participants allocated by alternation
Moues 2004 Not a diabetic foot wound study population
Perez 2010 Included multiple wounds types. Unable to obtain diabetic foot wound data separately
Rahmanian-Schwarz 2012 Included multiple wounds types. Unable to obtain diabetic foot wound data separately
Riaz 2010 Included wounds in people with diabetes in regions other than the foot (legs and back). Unable to
obtain diabetic foot wound data separately
Sepulveda 2009 No relevant outcome reported
Abbreviations
NPWT = negative pressure wound therapy
RCT = randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Sun 2007
Methods Not clear: could be an RCT
Participants People with DM and foot ulcers n = 38
Interventions NPWT
Outcomes Not clear - seems to be wound dimensions
Notes Requires translation from Chinese
Tuncel 2013
Methods RCT
Participants Mixed - request data for foot wound participants and further details
Interventions NPWT
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Tuncel 2013 (Continued)
Outcomes Requested wound healing data from authors
Notes
Abbreviations
DM = diabetes mellitus
NPWT = negative pressure wound therapy
RCT = randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
ISRCTN34166832
Trial name or title RCT PICO pilot study (Smith and Nephew)
Methods RCT
Participants Chronic and sub-acute wounds (some potentially foot wounds in people with DM). Planned sample size of
100
Interventions NPWT vs standard care
Outcomes Time to wound closure
Starting date
Contact information Emma.Whatley@smith-nephew.com
Notes ISRCTN record states end date of Aug 2012. Project Manager e-mail: “I can confirm that recruitment for
the study has not yet finished and that we currently have no DFU’s in the study. We expect that this might
change with the possible addition of a new site. We are hoping to have some data by the middle of next year.”
ISRCTN90301130
Trial name or title Treatment of diabetic foot wounds by Vacuum-Assisted Closure (VAC®): A multi-centre randomised con-
trolled trial (KCI)
Methods RCT
Participants Chronic or post-amputation wounds on the feet of people with diabetes
Interventions NPWT vs conventional moist wound therapy
Outcomes Time to complete healing, percentage of wounds closed, recurrence, resource use, adverse events
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ISRCTN90301130 (Continued)
Starting date June 2011
Contact information Ms D Seidel: doerthe.seidel@uni-wh.de
Notes End date cited as Sept 2013
Abbreviations
DM = diabetes mellitus
DFU = diabetic foot ulcer
NPWT = negative pressure wound therapy
RCT = randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. NPWT compared with moist (non-gauze) wound dressings
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of wounds healed 2 503 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [1.18, 1.84]
2 Time to healing 2 Hazard Ratio (Fixed, 95% CI) 1.85 [1.40, 2.45]
3 Amputations 2 503 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.17, 0.74]
4 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 All adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Treatment-related adverse
events
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. NPWT compared with gauze dressings
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of wounds healed 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 NPWT compared with moist (non-gauze) wound dressings, Outcome 1
Proportion of wounds healed.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 1 NPWT compared with moist (non-gauze) wound dressings
Outcome: 1 Proportion of wounds healed
Study or subgroup NPWT Moist dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Armstrong 2005 43/77 33/85 39.3 % 1.44 [ 1.03, 2.01 ]
Blume 2008 73/172 48/169 60.7 % 1.49 [ 1.11, 2.01 ]
Total (95% CI) 249 254 100.0 % 1.47 [ 1.18, 1.84 ]
Total events: 116 (NPWT), 81 (Moist dressings)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.41 (P = 0.00065)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours moist dressings Favours NPWT
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Analysis 1.2. Comparison 1 NPWT compared with moist (non-gauze) wound dressings, Outcome 2 Time
to healing.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 1 NPWT compared with moist (non-gauze) wound dressings
Outcome: 2 Time to healing
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Armstrong 2005 0.645 (0.23) 38.5 % 1.91 [ 1.21, 2.99 ]
Blume 2008 0.598 (0.182) 61.5 % 1.82 [ 1.27, 2.60 ]
Total (95% CI) 100.0 % 1.85 [ 1.40, 2.45 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.32 (P = 0.000016)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours moist dressing Favours NPWT
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Analysis 1.3. Comparison 1 NPWT compared with moist (non-gauze) wound dressings, Outcome 3
Amputations.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 1 NPWT compared with moist (non-gauze) wound dressings
Outcome: 3 Amputations
Study or subgroup NPWT Moist dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Armstrong 2005 2/77 9/85 33.3 % 0.25 [ 0.05, 1.10 ]
Blume 2008 7/172 17/169 66.7 % 0.40 [ 0.17, 0.95 ]
Total (95% CI) 249 254 100.0 % 0.35 [ 0.17, 0.74 ]
Total events: 9 (NPWT), 26 (Moist dressings)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.77 (P = 0.0056)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NPWT Favours moist dressings
Analysis 1.4. Comparison 1 NPWT compared with moist (non-gauze) wound dressings, Outcome 4
Adverse events.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 1 NPWT compared with moist (non-gauze) wound dressings
Outcome: 4 Adverse events
Study or subgroup NPWT Moist dressings Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All adverse events
Armstrong 2005 40/77 46/85 0.96 [ 0.72, 1.28 ]
2 Treatment-related adverse events
Armstrong 2005 9/77 11/85 0.90 [ 0.40, 2.06 ]
0.01 0.1 1 10 100
Favours moist dressings Favours NPWT
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Analysis 2.1. Comparison 2 NPWT compared with gauze dressings, Outcome 1 Proportion of wounds
healed.
Review: Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Comparison: 2 NPWT compared with gauze dressings
Outcome: 1 Proportion of wounds healed
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mody 2008 1/6 4/9 0.38 [ 0.05, 2.59 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (NPWT), 4 (Dressings)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dressings Favours NPWT
A D D I T I O N A L T A B L E S
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Table 1. Overview of trials
Armstrong 2005 16 weeks Diabetic foot am-
putation to trans-
metatarsal level
Group A: moist
wound therapy with
alginates, hydrocol-
loid, foam or hydro-
gel dressings (n = 85)
Group B: NPWT
(VAC system, dress-
ing changes every 48
h. Treatment con-
ducted until wound
closure or comple-
tion of 112-day as-
sessment (n = 77)
Number of wounds
completely healed
Group A: 33/85 (38.
8%)
Group B: 43/77 (55.
8%)
Of healed wounds -
healed by secondary
in-
tention (without pri-
mary/surgical wound
closure)
Group A: 25/33 (75.
8%)
Group B: 31/43 (72.
1%)
Remaining wounds
were closed follow-
ing surgery.
Time to wound
healing
median time to heal-
ing
Group A: 77 days
(IQR 40 to 122)
Group B: 56 days
(IQR 26 to 92)
Log rank = p = 0.005
Amputation
Number of partici-
pants undergoing fur-
ther amputation
Group A: 9/85 (10.
6%)
Major = 5/Minor = 4
Group B: 2/77 (2.
3%)
Major = 0/Minor = 2
There was no differ-
ence noted in time to
healing for acute or
chronic wounds
Adverse events
Participants who had
one or more adverse
events
Group A: 46/85 (54.
1%)
Group B: 40/77 (51.
9%)
Participants who had
one or more treat-
ment-related adverse
events
Group A: 11/85 (12.
9%)
5 classified as serious
Group B: 9/77 (11.
7%)
1 classified serious
Resource use
Average total cost per
participant
Group A: USD 36,
887
Group B: USD26,
972
Average total direct
cost per participants
for those treated for 8
weeks or longer
Group A: USD 36,
096
Group B: USD 27,
270
Average per partici-
pant cost to achieve
100% healing
Group A: USD 38,
806
Group B: USD 25,
954
Blume 2008 16 weeks Ulceration of the
foot in people with
diabetes
Group A: advanced
moist wound ther-
apy dressings used
according to guide-
lines/local protocols
(n = 169)
Number of wounds
completely healed
(six participants ex-
cluded in paper as
did not receive treat-
ment,
Adverse events
Limited data: not ex-
tracted
Resource use -
taken from confer-
ence abstract that
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Table 1. Overview of trials (Continued)
Group B: NPWT
(VAC system)
, applied according
tomanufacturer’s in-
structions. (n = 172)
added back into de-
nominator here)
Group A: 48/169
(28.4%)
Group B: 73/172
(42.4%)
Proportion of wounds
closed using surgery
(unclear if considered
part of healed group)
Group A: 14/169 (8.
3%)
Group B: 16/172 (9.
3%)
Time to wound
healing
median time to heal-
ing
Group A: could not
be estimated
Group B: 96 days
(95% CI 75.0 to
114.0)
Log rank taken as P
value 0.001
Amputation
Number of partici-
pants undergoing am-
putation*
Group A: 17/169
(10.1%)
Major = 4; minor =
13
Group B: 7/172 (4.
1%)
Major = 5; minor =
2
we think is related
to this main publi-
cation.
Mean estimated total
costs of inpatient ser-
vices per participant
Group A:
USD 8570 (95%CI
USD 5922 to USD
11,432)
Group B: USD
5206 (95%CI USD
3172 to USD 7561)
Karatepe 2011 Not specified.
Last assessment one
month after healing
Diabetic foot ulcers Group A: conven-
tional wound care
treatment: based on
text in report taken
to be dry gauze (n =
37)
Group B: NPWT
(VAC system) (n =
30)
Time to healing
Median time toheal-
ing
Group A: 4.4 weeks
Group B: 3.9 weeks
Mean value presented
but not extracted.
No specific P value
presented
Health-related
quality of life
SF-36:Data not pre-
sented.
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Table 1. Overview of trials (Continued)
Mody 2008 Not specified: until
healing or loss to fol-
low-up
Diabetic foot ulcers GroupA: wet-to-dry
gauze (n = 9)
Group B: locally-
constructed NPWT
(n = 6)
Number of wounds
completely healed
By secondary inten-
tion:
Group A: 1/9 (11.
0%)
Group B: 1/6 (16.
6%)
By delayed primary
closure:
Group A: 3/9 (33%)
Group B: 0/6 (0%)
Novinš ak 2010 2 months Complicated
diabetic foot ulcers
Group A: classic
gauze (n = 8)
Group B: dressings
(moist) (n = 12)
GroupC:NPWT (n
= 7)
Healing rate (per-
centage with
wound closure - de-
fined by author on
contact)
Group A: 4/8*
(50%)
Group B: 9/12*
(75%)
Group C: * could
not be calculated
(90%)
*Figure cal-
culated by review au-
thor as only propor-
tions obtained from
study author
WH A T ’ S N E W
Last assessed as up-to-date: 30 July 2013.
Date Event Description
3 June 2014 Amended Edits to Table labels
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